TrialCancer medicine2021

Combination of body mass index and albumin predicts the survival in metastatic castration-resistant prostate cancer patients treated with abiraterone: A post hoc analysis of two randomized trials.

Jian Pan et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.